Minimising medication mishap: Introducing a warfarin safety strategy

Journal of Pharmacy Practice and Research

Volumn 35, Issue 4, 2005, Pages 266-270

  Lubliner, Mark ^a   Cole Sinclair, Merrole ^b   Kenneally, Anne ^b   Street, Alison ^b   Van De Vreede, Melita ^c,d   Walsh, Michael K ^c  

^a Alfred Health   (Australia)

^b Haemostasis Thrombosis Unit   (Australia)

^c BAYSIDE HEALTH   (Australia)

^d Pharmacy Department   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; WARFARIN;

BLEEDING; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MEDICATION ERROR; PATIENT EDUCATION; PRESCRIPTION; PROTHROMBIN TIME; REVIEW;

EID: 32644440943     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2005.tb00360.x     Document Type: Review

References (19)

1. Leape LL, Brennan TA, Laird NM, Lawthers AG, Localio AR, Barnes BA, et al. The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med 1991; 324: 377-84.
2. Wilson RM, Runciman WB, Gibberd RW, Harrison BT, Newby L, Hamilton JD. The quality in Australian health care study. Med J Aust 1995; 163: 458-71.
3. Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, Lawthers AG, et al. Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice Study I. N Engl J Med 1991; 324: 370-6.
4. Malpass A, Helps SC, Sexton BJ, Maiale D, Runciman WB. A classification for adverse drug events. J Qual Clin Pract 1999; 19: 23-6.
5. Gallus AS, Baker RI, Chong BH, Ockelford PA, Street AM. Consensus guidelines for warfarin therapy. Med J Aust 2000; 172: 600-5.
6. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy. Arch Intern Med 1993; 153: 1557-62.
7. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-17.
8. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 1998; 114 (suppl. 5): S511-S523.
9. Laupaeis A, Boysen G, Connolly S, Ezekowitz M, Hart R, James K, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154: 1449-57.
10. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation anil recent cerebral ischemia. N Engl J Med 1995; 333: 5-10.
11. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42: 857-65.
12. Landefeld S, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 1993; 95: 315-28.
13. Film SD, McDonell M, Martin D, Henikoff J, Venues D, Kent D. et al. Risk factors for complications of chronic anticoagulation. Ann Intern Med 1993; 118: 511-20.
14. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort. prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-8.
15. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
16. Leape LL. Error in medicine. JAMA 1994; 272: 1851-7.
17. Reason J. Human Error. New York: Cambridge University Press; 1990.
18. Vincent C, Taylor-Adams S, Stanhope N. Framework for analysing risk and safety in clinical medicine. BMJ 1998; 316: 1154-7.
19. Kotter JP. Leading change: why transformation efforts fail. Harvard Bus Rev 1995; March-April: 59-67.